30.04.2013 • News

Clariant, SK Capital Report on Progress of the Textile, Paper and Emulsions Activities Divestment

Clariant and SK Capital, a private investment firm with a disciplined focus on the specialty materials, chemicals and healthcare sectors, provided an update on the separation process of Textile Chemicals, Paper Specialties and Emulsions. Clariant announced that it agreed to sell the three businesses to SK Capital on 27 December 2012.

After closing of the transaction, the three businesses will be regrouped under a new company with the name of Archroma. Archroma will be a supplier of products and solutions to the textile, paper, adhesives and coating industries with a turnover of CHF 1.2 billion and approximately 3,000 employees. The company will be headquartered in Switzerland, which will also host the leadership of Archroma Paper Solutions. Archroma Textile Specialties will be managed from Singapore and Archroma Emulsions Products will be managed from Brazil.

The operational and legal separation, including the incorporation of legal entities, licensing and registration activities, the establishment of IT systems, and development of infrastructure and support services as well as ensuring a seamless transition for the Archroma employees is proceeding well.

An important aspect in establishing the new company is obtaining merger control and governmental approvals and authorizations, several of which remain pending. To ensure a successful separation process that minimizes disruption for both customers and employees, Clariant and SK Capital have targeted a closing of the transaction at the end of the 3rd quarter of 2013.

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.